[HTML][HTML] Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
J DeFalco, M Harbell, A Manning-Bog, G Baia… - Clinical …, 2018 - Elsevier
There is significant debate regarding whether B cells and their antibodies contribute to
effective anti-cancer immune responses. Here we show that patients with metastatic but non-
progressing melanoma, lung adenocarcinoma, or renal cell carcinoma exhibited increased
levels of blood plasmablasts. We used a cell-barcoding technology to sequence their
plasmablast antibody repertoires, revealing clonal families of affinity matured B cells that
exhibit progressive class switching and persistence over time. Anti-CTLA4 and other …
effective anti-cancer immune responses. Here we show that patients with metastatic but non-
progressing melanoma, lung adenocarcinoma, or renal cell carcinoma exhibited increased
levels of blood plasmablasts. We used a cell-barcoding technology to sequence their
plasmablast antibody repertoires, revealing clonal families of affinity matured B cells that
exhibit progressive class switching and persistence over time. Anti-CTLA4 and other …